A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and
efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in
participants with previously treated hematological cancers including acute lymphocytic
leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL),
follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM),
mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma
(RTL), and T-cell non-Hodgkin lymphoma (NHL).